Organon & Co | OGN - Passivo Circulante





Passivo Circulante Alterar Data
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Celltrion KRW 283.62B 3.72T 2025-12
Cspc Pharmaceutical CNY 10.18B 65.36M 2025-12
Deva Holding AS TRY 6.43B 1.18B 2023-09
Dianthus Therapeutics USD 38.28M 7.55M 2026-03
Divis Laboratories Ltd INR 17.28B 2.76B 2025-09
Gilead Sciences USD 9.48B 2.34B 2026-03
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Kangmei Pharma CNY 5.81B 57.93M 2025-09
Knight Therapeutics CAD 165.26M 12.58M 2025-12
Laboratorios Farma EUR 199.84M 121.75M 2023-12
Malin Corporation EUR 1000K 500K 2024-12
Medical Developments International AUD 5.56M 2.26M 2025-12
Merck USD 26.94B 1.38B 2026-03
Neuren Pharmaceuticals AUD 4.34M 3.58M 2025-12
Novartis USD 27.28B 4.72B 2025-12
Organigram Holdings CAD 94.05M 32.11M 2025-12
Organon & Co USD 2.5B 110M 2026-03
Ovoca Bio EUR 186K 2.26M 2025-06
Pharma Mar EUR 89.23M 4.65M 2026-03
Qiagen NV USD 512.14M 461.26M 2025-12
Sartorius EUR 2.11B 145.8M 2026-03
Sino Biopharmaceutical CNY 24.85B 5.29B 2025-06
Tilray USD 259.32M 8.32M 2025-09
Zealand Pharma A/S 664.96M 513.61M 2025-12